President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

Panelist discusses how HS Centers of Excellence integrating multidisciplinary care, personalized treatments, comprehensive tracking, and holistic patient support strategies can significantly improve ...

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

The upcoming Supreme Court hearing on Braidwood Management v Becerra could affect how preventive services are covered by both ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

In part 3 of this conversation, Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, discusses ...

The clinical and financial implications of inpatient dermatology were examined, highlighting the need for systemic changes to ...

While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol ...

Increasing testing for both HIV and sexually transmitted infections (STIs) can help to mitigate the incidence of both in high school students.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.